共 35 条
- [31] Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report [J]. BLOOD, 2020, 136
- [34] A Randomized Phase 3 Trial of Blinatumomab Vs Chemotherapy as Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-Acute Lymphoblastic Leukemia in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report From Children's Oncology Group Study AALL1331 [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 13 - 14
- [35] A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331 [J]. BLOOD, 2019, 134